Lyell Immunopharma, Inc. (LYEL) - What Are Analysts Saying About This Stock?

Key Points

• Analyst sentiment is moderately positive: Lyell Immunopharma has an average “Moderate Buy” rating, with six buys, one strong buy, one hold, and one sell. The average 12-month price target is $40.86.
• Institutional ownership is substantial: Institutional investors own 66.05% of LYEL, with several hedge funds and asset managers recently establishing or increasing positions.
• The company remains financially challenged: Shares opened at $9.31, well below the 52-week high of $45.00, while Lyell reported a quarterly loss of $1.92 per share, no revenue, and expects a full-year loss of $7.16 per share.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) has been given an average rating of "Moderate Buy" by the nine ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $40.86.

A number of equities analysts have recently commented on LYEL shares. Citigroup reiterated a "market outperform" rating on shares of Lyell Immunopharma in a report on Friday, August 14th. Needham & Company LLC restated a "buy" rating and issued a $44.00 price objective on shares of Lyell Immunopharma in a report on Friday, September 11th. Royal Bank Of Canada set a $34.00 price objective on Lyell Immunopharma in a report on Friday, August 14th. Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Sunday. Finally, Stifel Nicolaus assumed coverage on Lyell Immunopharma in a report on Thursday, August 6th. They set a "buy" rating and a $36.00 target price on the stock.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new position in shares of Lyell Immunopharma in the second quarter worth approximately $347,000. Walleye Capital LLC bought a new stake in Lyell Immunopharma in the first quarter valued at approximately $445,000. Squarepoint Ops LLC increased its position in Lyell Immunopharma by 119.4% during the 2nd quarter. Squarepoint Ops LLC now owns 42,322 shares of the company's stock valued at $595,000 after purchasing an additional 23,028 shares during the period. Bank of America Corp DE increased its position in Lyell Immunopharma by 314.2% during the 1st quarter. Bank of America Corp DE now owns 33,321 shares of the company's stock valued at $668,000 after purchasing an additional 25,276 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in Lyell Immunopharma during the 1st quarter valued at approximately $959,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Price Performance

LYEL stock opened at $9.31 on Tuesday. The company has a 50 day simple moving average of $11.36 and a 200 day simple moving average of $17.17. The stock has a market cap of $228.09 million, a price-to-earnings ratio of -0.73 and a beta of -0.03. Lyell Immunopharma has a 1 year low of $7.20 and a 1 year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. The business had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.00 million. On average, equities research analysts anticipate that Lyell Immunopharma will post -7.16 EPS for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell's research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.